Bookmark and Share
BioAssay: AID 588729

Late stage counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): Absorbance-based cell-based assay to identify modulators of cancer cell viability

Name: Late stage counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): Absorbance-based cell-based assay to identify modulators of cancer cell viability. ..more
_
   
 Tested Compounds
 Tested Compounds
All(1)
 
 
Unspecified(1)
 
 
 Tested Substances
 Tested Substances
All(1)
 
 
Unspecified(1)
 
 
 Related BioAssays
 Related BioAssays
AID: 588729
Data Source: The Scripps Research Institute Molecular Screening Center (NCI60_INH_ABS_2XIC50 MDCSRUN SAR)
BioAssay Type: Panel, Confirmatory, Concentration-Response Relationship Observed
Depositor Category: NIH Molecular Libraries Probe Production Network
Deposit Date: 2011-10-30
Hold-until Date: 2012-10-27
Modify Date: 2012-10-27

Data Table ( Complete ):           View All Data
Tested Compound:
Related Experiments
Show more
AIDNameTypeComment
1700Primary cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)Screeningdepositor-specified cross reference: Primary screen (KLF5 inhibitors in singlicate)
1825Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.Screeningdepositor-specified cross reference: Counterscreen (Cytotoxic compounds in singlicate)
1834Luminescence-based confirmation cell-based high throughput screening assay to identify inhibitors of kruppel-like factor 5 (KLF5)Screeningdepositor-specified cross reference: Confirmation screen (KLF5 inhibitors in triplicate)
1858Summary of probe development efforts to identify inhibitors of kruppel-like factor 5 (KLF5)Summarydepositor-specified cross reference: Summary (KLF5 inhibitors)
1905Luminescence-based counterscreen assay for KLF5 inhibitors: cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line in triplicate.Screeningdepositor-specified cross reference: Counterscreen (Cytotoxic compounds in triplicate)
1907Luminescence-based confirmation cell-based assay for cytotoxic compounds using the IEC-6 intestinal epithelial cell line.Screeningdepositor-specified cross reference: Confirmation screen (Cytotoxic compounds in triplicate)
1972Luminescence-based dose response cell-based high throughput screening assay for cytotoxic compounds using the IEC-6 intestinal epithelial cell line.Confirmatorydepositor-specified cross reference: Dose response (Cytotoxic compounds in triplicate)
1973Luminescence-based dose response cell-based high throughput screening assay for inhibitors of kruppel-like factor 5 (KLF5).Confirmatorydepositor-specified cross reference: Dose response (KLF5 inhibitors in triplicate)
1975Luminescence-based counterscreen assay for KLF5 inhibitors: dose response cell-based high throughput screening assay to identify cytotoxic compounds using the IEC-6 intestinal epithelial cell line.Confirmatorydepositor-specified cross reference: Dose response counterscreen (Cytotoxic compounds in triplicate)
2749Late stage counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): luminescence-based cell-based dose response assay for cytotoxic compounds using the IEC-6 intestinal epithelial cell lineConfirmatorydepositor-specified cross reference: Late stage counterscreen dose response (Cytotoxic compounds in triplicate)
2750Late stage results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): luminescence-based cell-based dose response assay for inhibitors of KLF5Confirmatorydepositor-specified cross reference: Late stage dose response (KLF5 inhibitors in triplicate)
434956Late stage counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): luminescence-based cell-based dose response assay for cytotoxic compounds using the IEC-6 intestinal epithelial cell line (Round 1)Confirmatorydepositor-specified cross reference: Late stage dose response counterscreen (Cytotoxic compounds in triplicate)
434957Late stage results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): luminescence-based cell-based dose response assay for inhibitors of KLF5 (Round 1)Confirmatorydepositor-specified cross reference: Late stage dose response (KLF5 inhibitors in triplicate)
485336Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of KLF5 protein levelsConfirmatorydepositor-specified cross reference: Late stage dose response (KLF5 protein levels inhibitors in triplicate)
485338Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): luminescence-based cell-based dose response assay for cytotoxic compounds using the DLD-1 cell line (Round 1)Confirmatorydepositor-specified cross reference: Late stage dose response counterscreen (Cytotoxicity in triplicate)
588539Late stage assay provider counterscreen results for the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): Cell cycle analysis of the DLD-1 cell lineOtherdepositor-specified cross reference: Late stage counterscreen (Cell cycle analysis of the DLD-1 cell line)
588610Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Epidermal Growth Factor Receptor (EGFR) protein levels in DLD1 cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGFR protein levels in DLD1 cells inhibitors)
588612Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Mitogen-Activated Protein Kinase 1 (P-MAPK1; P-ERK1/2) protein levels in DLD1 cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-ERK1/2 protein levels in DLD1 cells inhibitors)
588613Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Epidermal Growth Factor Receptor (EGFR) protein levels in DLD1 cells.Otherdepositor-specified cross reference: Late stage counterscreen (P-EGFR protein levels in DLD1 cells inhibitors)
588614Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Mitogen-Activated Protein Kinase 1 (MAPK1; ERK1/2) protein levels in DLD1 cellsOtherdepositor-specified cross reference: Late stage counterscreen (ERK1/2 protein levels in DLD1 cells inhibitors)
588615Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of P38 protein levels in DLD1 cellsOtherdepositor-specified cross reference: Late stage counterscreen (P38 protein levels in DLD1 cells inhibitors)
588616Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of phospho-P38 protein levels in DLD1 cellsOtherdepositor-specified cross reference: Late stage counterscreen (phospho-P38 protein levels in DLD1 cells inhibitors)
588617Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of KLF5 protein levels in DLD1 cellsOtherdepositor-specified cross reference: Late stage counterscreen (KLF5 protein levels in DLD1 cells inhibitors)
588618Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Early Growth Response 1 (EGR1) protein levels in DLD1 cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGR1 protein levels in DLD1 cells inhibitors)
588640Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of P38 protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P38 protein levels in HCT116 cells inhibitors)
588642Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Mitogen-Activated Protein Kinase 1 (MAPK1; ERK1/2) protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (ERK1/2 protein levels in HCT116 cells inhibitors)
588643Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Mitogen-Activated Protein Kinase 1 (P-MAPK1; P-ERK1/2) protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-ERK1/2 protein levels in HCT116 cells inhibitors)
588644Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Early Growth Response 1 (EGR1) protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGR1 protein levels in HCT116 cells inhibitors)
588646Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of phosphorylated P38 protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (phospho-P38 protein levels in HCT116 cells inhibitors)
588648Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Epidermal Growth Factor Receptor (EGFR) protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGFR protein levels in HCT116 cells inhibitors)
588650Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Epidermal Growth Factor Receptor (EGFR) protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-EGFR protein levels in HCT116 cells inhibitors)
588652Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of KLF5 protein levels in HCT116 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (KLF5 protein levels in HCT116 cells inhibitors)
588653Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Epidermal Growth Factor Receptor (EGFR) protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-EGFR protein levels in HT29 cells inhibitors)
588654Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Epidermal Growth Factor Receptor (EGFR) protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGFR protein levels in HT29 cells inhibitors)
588655Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Mitogen-Activated Protein Kinase 1 (P-MAPK1; P-ERK1/2) protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-ERK1/2 protein levels in HT29 cells inhibitors)
588656Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Mitogen-Activated Protein Kinase 1 (MAPK1; ERK1/2) protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (ERK1/2 protein levels in HT29 cells inhibitors)
588657Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Early Growth Response 1 (EGR1) protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGR1 protein levels in HT29 cells inhibitors)
588658Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of phosphorylated P38 protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (phospho-P38 protein levels in HT29 cells inhibitors)
588659Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of P38 protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P38 protein levels in HT29 cells inhibitors)
588660Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of KLF5 protein levels in HT29 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (KLF5 protein levels in HT29 cells inhibitors)
588661Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of KLF5 protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (KLF5 protein levels in SW620 cells inhibitors)
588662Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of P38 protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P38 protein levels in SW620 cells inhibitors)
588663Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of phosphorylated P38 protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-P38 protein levels in SW620 cells inhibitors)
588665Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Early Growth Response 1 (EGR1) protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGR1 protein levels in SW620 cells inhibitors)
588666Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Mitogen-Activated Protein Kinase 1 (MAPK1; ERK1/2) protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (ERK1/2 protein levels in SW620 cells inhibitors)
588667Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Epidermal Growth Factor Receptor (EGFR) protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (EGFR protein levels in SW620 cells inhibitors)
588668Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Mitogen-Activated Protein Kinase 1 (P-MAPK1; P-ERK1/2) protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-ERK1/2 protein levels in SW620 cells inhibitors)
588677Late stage assay provider counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): chemiluminescence-based western blot assay for inhibitors of Phosphorylated Epidermal Growth Factor Receptor (EGFR) protein levels in SW620 human colorectal carcinoma cellsOtherdepositor-specified cross reference: Late stage counterscreen (P-EGFR protein levels in SW620 cells inhibitors)
588725Late stage counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): Radioactivity-based biochemical assay to identify modulators of a panel of 48 kinasesOthersame project related to Summary assay
Description:
Source (MLPCN Center Name): The Scripps Research Institute Molecular Screening Center
Affiliation: The Scripps Research Institute, TSRI
Assay Provider: Vincent Yang, Emory University
Network: Molecular Library Probe Production Centers Network (MLPCN)
Grant Proposal Number: 1-R03-DA026215-01
Grant Proposal PI: Vincent Yang
External Assay ID: NCI60_INH_ABS_2XIC50 MDCSRUN SAR

Name: Late stage counterscreen results from the probe development effort to identify inhibitors of kruppel-like factor 5 (KLF5): Absorbance-based cell-based assay to identify modulators of cancer cell viability.

Description:

Transcription factors are essential regulators of transcription that bind DNA to control both the rate and frequency of gene expression (1). Many diseases of cell homeostasis are associated with aberrant transcription factor activity (2). Colon cancer, in particular, is a disease of uncontrolled proliferation of the epithelial cells that line the intestinal crypts. Kruppel-like factor 5 (KLF5) is a zinc finger-containing transcription factor that binds to GC-rich sequences in promoters of numerous genes (3) including cyclin D1 (4), cyclin B1/Cdc2 (4), and integrin-linked kinase (5). KLF5 is highly expressed in rapidly dividing epithelial cells in intestinal crypts (6). This expression pattern of KLF5, along with studies demonstrating that KLF5 mediates the transforming effects of oncogenic H-Ras (7), and that ectopic expression of KLF5 leads to increased cell proliferation and anchorage-independent growth of cultured intestinal epithelial cells (8, 9), suggest that KLF5 may be involved in colon cancer pathogenesis. Therefore, the identification of selective inhibitors of KLF5 may provide useful tools to elucidate the role of KLF5 as a regulator of cellular proliferation and tumor formation in the intestinal epithelium (10).

References:

1. Ptashne M. Regulation of transcription: from lambda to eukaryotes. Trends Biochem Sci. 2005 Jun;30(6):275-9.
2. Fre S, Vignjevic D, Schoumacher M, Duffy SL, Janssen KP, Robine S, Louvard D. Adv Cancer Res. 2008;100:85-111. Epithelial morphogenesis and intestinal cancer: new insights in signaling mechanisms.
3. Goldstein BG, Chao HH, Yang Y, Yermolina YA, Tobias JW, Katz JP. Am J Physiol Gastrointest Liver Physiol. 2007 Jun;292(6):G1784-92. Overexpression of Kruppel-like factor 5 in esophageal epithelia in vivo leads to increased proliferation in basal but not suprabasal cells.
4. Ghaleb AM, Nandan MO, Chanchevalap S, Dalton WB, Hisamuddin IM, Yang VW. Kruppel-like factors 4 and 5: the yin and yang regulators of cellular proliferation. Cell Res. 2005 Feb;15(2):92-6.
5. Yang Y, Tetreault MP, Yermolina YA, Goldstein BG, Katz JP. Kruppel-like factor 5 controls keratinocyte migration via the integrin-linked kinase. J Biol Chem. 2008 Jul 4;283(27):18812-20.
6. McConnell BB, Ghaleb AM, Nandan MO, Yang VW. The diverse functions of Kruppel-like factors 4 and 5 in epithelial biology and pathobiology. Bioessays. 2007 Jun;29(6):549-57. Erratum in: Bioessays. 2007 Sep;29(9):946.
7. Nandan MO, Yoon HS, Zhao W, Ouko LA, Chanchevalap S, Yang VW. Kruppel-like factor 5 mediates the transforming activity of oncogenic H-Ras. Oncogene. 2004 Apr 22;23(19):3404-13.
8. Chanchevalap S, Nandan MO, Merlin D, Yang VW. FEBS Lett. 2004 Dec 3;578(1-2):99-105. All-trans retinoic acid inhibits proliferation of intestinal epithelial cells by inhibiting expression of the gene encoding Kruppel-like factor 5.
9. Sun R, Chen X, Yang VW. J Biol Chem. 2001 Mar 9;276(10):6897-900. Intestinal-enriched Kruppel-like factor (Kruppel-like factor 5) is a positive regulator of cellular proliferation.
10. Bialkowska A, Crisp M, Bannister T, He Y, Chowdhury S, Schurer S, Chase P, Spicer T, Madoux F, Tian. Identification of Small-Molecule Inhibitors of the Colorectal Cancer Oncogene Kruppel-Like Factor 5 Expression by Ultrahigh-Throughput Screening. Mol Canc Ther. 2011.

Keywords:

Late stage, late stage AID, NCI60, cell growth, proliferation, viability, cytotoxicity, profiling, outsource, panel, ATP, powders, purchased, synthesized, cells, cell viability, cell, KLF5, BTEB2, kruppel-like factor 5, cancer, dose response, counterscreen, selectivity, inhibitor, inhibition, assay provider, Scripps, Scripps Florida, The Scripps Research Institute Molecular Screening Center, SRIMSC, Molecular Libraries Probe Production Centers Network, MLPCN.
Panel Information
Cell Lines
    Data Table(All)Show more
PID§NameSubstancePanel TargetsDescription
ActiveInactive
1CCRF-CEM [Leukemia]1
2HL-60(TB) [Leukemia]1
3MOLT-4 [Leukemia]1
4RPMI-8226 [Leukemia]1
5SR [Leukemia]1
6A549/ATCC [Non-Small Cell Lung Cancer]1
7EKVX [Non-Small Cell Lung Cancer]1
8HOP-62 [Non-Small Cell Lung Cancer]1
9HOP-92 [Non-Small Cell Lung Cancer]1
10NCI-H226 [Non-Small Cell Lung Cancer]1
11NCI-H322M [Non-Small Cell Lung Cancer]1
12NCI-H460 [Non-Small Cell Lung Cancer]1
13NCI-H522 [Non-Small Cell Lung Cancer]1
14COLO 205 [Colon Cancer]1
15HCC-2998 [Colon Cancer]1
16HCT-116 [Colon Cancer]1
17HCT-15 [Colon Cancer]1
18HT29 [Colon Cancer]1
19KM12 [Colon Cancer]1
20SW-620 [Colon Cancer]1
21SF-268 [CNS Cancer]1
22SF-295 [CNS Cancer]1
23SF-539 [CNS Cancer]1
24SNB-19 [CNS Cancer]1
25SNB-75 [CNS Cancer]1
26U251 [CNS Cancer]1
27LOX IMVI [Melanoma]1
28MALME-3M [Melanoma]1
29M14 [Melanoma]1
30MDA-MB-435 [Melanoma]1
31SK-MEL-2 [Melanoma]1
32SK-MEL-28 [Melanoma]1
33UACC-257 [Melanoma]1
34UACC-62 [Melanoma]1
35IGROV1 [Ovarian Cancer]1
36OVCAR-3 [Ovarian Cancer]1
37OVCAR-4 [Ovarian Cancer]1
38OVCAR-5 [Ovarian Cancer]1
39OVCAR-8 [Ovarian Cancer]1
40NCI/ADR-RES [Ovarian Cancer]1
41SK-OV-3 [Ovarian Cancer]1
42786-0 [Renal Cancer]1
43A498 [Renal Cancer]1
44ACHN [Renal Cancer]1
45CAKI-1 [Renal Cancer]1
46RXF 393 [Renal Cancer]1
47SN12C [Renal Cancer]1
48TK-10 [Renal Cancer]1
49UO-31 [Renal Cancer]1
50PC-3 [Prostate Cancer]1
51DU-145 [Prostate Cancer]1
52MCF7 [Breast Cancer]1
53MDA-MB-231/ATCC [Breast Cancer]1
54HS 578T [Breast Cancer]1
55BT-549 [Breast Cancer]1
56T-47D [Breast Cancer]1

§ Panel component ID.
Protocol
Assay Overview:
The purpose of this assay is to determine whether a powder sample of a possible KLF5 inhibitor probe candidate can inhibit growth of colon cancer and other NCI60 panel cancer cell lines.
Protocol Summary:
The human tumor cell lines of the cancer screening panel are grown in RPMI 1640 medium containing 5% fetal bovine serum and 2 mM L-glutamine. For a typical screening experiment, cells are inoculated into 96 well microtiter plates in 100 uL at plating densities ranging from 5,000 to 40,000 cells/well depending on the doubling time of individual cell lines. After cell inoculation, the microtiter plates are incubated at 37 C, 5% CO2, 95% air and 100% relative humidity for 24 h prior to addition of experimental drugs.
After 24 h, two plates of each cell line are fixed in situ with TCA, to represent a measurement of the cell population for each cell line at the time of drug addition (Tz). Experimental drugs are solubilized in dimethyl sulfoxide at 400-fold the desired final maximum test concentration and stored frozen prior to use. At the time of drug addition, an aliquot of frozen concentrate is thawed and diluted to twice the desired final maximum test concentration with complete medium containing 50 ug/ml gentamicin. Additional four, 10-fold or (1/2) log serial dilutions are made to provide a total of five drug concentrations plus control. Aliquots of 100 ul of these different drug dilutions are added to the appropriate microtiter wells already containing 100 ul of medium, resulting in the required final drug concentrations.
Following drug addition, the plates are incubated for an additional 48 h at 37 C, 5% CO2, 95% air, and 100% relative humidity. For adherent cells, the assay is terminated by the addition of cold TCA. Cells are fixed in situ by the gentle addition of 50 ul of cold 50% (w/v) TCA (final concentration, 10% TCA) and incubated for 60 minutes at 4 C. The supernatant is discarded, and the plates are washed five times with tap water and air dried. Sulforhodamine B (SRB) solution (100 ul) at 0.4% (w/v) in 1% acetic acid is added to each well, and plates are incubated for 10 minutes at room temperature. After staining, unbound dye is removed by washing five times with 1% acetic acid and the plates are air dried. Bound stain is subsequently solubilized with 10 mM trizma base, and the absorbance is read on an automated plate reader at a wavelength of 515 nm. For suspension cells, the methodology is the same except that the assay is terminated by fixing settled cells at the bottom of the wells by gently adding 50 ul of 80% TCA (final concentration, 16% TCA). Using the seven absorbance measurements [time zero, (Tz), control growth, (C), and test growth in the presence of drug at the five concentration levels (Ti)], the percentage growth is calculated at each of the drug concentrations levels.
Percentage growth inhibition is calculated as:
%_Growth_Inhibition = ( ( Ti - Tz ) / ( C - Tz ) ) * 100 for concentrations for which Ti >= Tz.
%_Growth_Inhibition = ( ( Ti - Tz ) / Tz ) * 100 for concentrations for which Ti < Tz.
Four dose response parameters are calculated for each experimental agent. Growth inhibition of 50% (GI50) is calculated from [(Ti-Tz)/(C-Tz)] x 100 = 50, which is the drug concentration resulting in a 50% reduction in the net protein increase (as measured by SRB staining) in control cells during the drug incubation. The drug concentration resulting in total growth inhibition (TGI) is calculated from Ti = Tz. The LC50 (concentration of drug resulting in a 50% reduction in the measured protein at the end of the drug treatment as compared to that at the beginning) indicating a net loss of cells following treatment is calculated from [(Ti-Tz)/Tz] x 100 = -50. The IC50 term is considered as the concentration at which 50% inhibition of growth occurs (provided by NCI). Values are calculated for each of these four parameters if the level of activity is reached; however, if the effect is not reached or is exceeded, the value for that parameter is expressed as greater or less than the maximum or minimum concentration tested.
PubChem Activity Outcome and Score:
For each cell line:
Compounds with a GI50 value equal to or less than 5 uM were considered active. Compounds with a GI50 value greater than 5 uM were considered inactive. These active compounds are potentially cytotoxic to cancer cells, or may interfere with the assay format or detection.
Comment
This assay was run by NCI. This assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided. Additional information can be found at http://dtp.nci.nih.gov/branches/btb/ivclsp.html
Categorized Comment - additional comments and annotations
From BioAssay Depositor:
BAO: assay design: viability reporter: dna content
BAO: bioassay specification: assay readout content: assay readout method: regular screening
BAO: bioassay specification: assay readout content: content readout type: single readout
BAO: detection technology: absorbance
BAO: meta target: biological process target: cell proliferation
BAO: version: 1.4b1090
From PubChem:
Assay Format: Cell-based
Result Definitions
Show more
TIDNameDescriptionPID§Panel TargetsHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
1Outcome [CCRF-CEM]bioassay outcome1Outcome
2GI50 [CCRF-CEM]*Concentration of a substance in units of molarity required for 50% growth inhibition.1FloatμM
3IC50 [CCRF-CEM]Concentration at which 50% inhibition occurs.1FloatμM
4LC50 [CCRF-CEM]Concentration of a substance in units of molarity required for total growth inhibition.1FloatμM
5TGI [CCRF-CEM]Concentration of a substance in units of molarity required for 50% lethal dose.1FloatμM
6Outcome [HL-60(TB)]bioassay outcome2Outcome
7GI50 [HL-60(TB)]*Concentration of a substance in units of molarity required for 50% growth inhibition.2FloatμM
8IC50 [HL-60(TB)]Concentration at which 50% inhibition occurs.2FloatμM
9LC50 [HL-60(TB)]Concentration of a substance in units of molarity required for total growth inhibition.2FloatμM
10TGI [HL-60(TB)]Concentration of a substance in units of molarity required for 50% lethal dose.2FloatμM
11Outcome [MOLT-4]bioassay outcome3Outcome
12GI50 [MOLT-4]*Concentration of a substance in units of molarity required for 50% growth inhibition.3FloatμM
13IC50 [MOLT-4]Concentration at which 50% inhibition occurs.3FloatμM
14LC50 [MOLT-4]Concentration of a substance in units of molarity required for total growth inhibition.3FloatμM
15TGI [MOLT-4]Concentration of a substance in units of molarity required for 50% lethal dose.3FloatμM
16Outcome [RPMI-8226]bioassay outcome4Outcome
17GI50 [RPMI-8226]*Concentration of a substance in units of molarity required for 50% growth inhibition.4FloatμM
18IC50 [RPMI-8226]Concentration at which 50% inhibition occurs.4FloatμM
19LC50 [RPMI-8226]Concentration of a substance in units of molarity required for total growth inhibition.4FloatμM
20TGI [RPMI-8226]Concentration of a substance in units of molarity required for 50% lethal dose.4FloatμM
21Outcome [SR]bioassay outcome5Outcome
22GI50 [SR]*Concentration of a substance in units of molarity required for 50% growth inhibition.5FloatμM
23IC50 [SR]Concentration at which 50% inhibition occurs.5FloatμM
24LC50 [SR]Concentration of a substance in units of molarity required for total growth inhibition.5FloatμM
25TGI [SR]Concentration of a substance in units of molarity required for 50% lethal dose.5FloatμM
26Outcome [A549/ATCC]bioassay outcome6Outcome
27GI50 [A549/ATCC]*Concentration of a substance in units of molarity required for 50% growth inhibition.6FloatμM
28IC50 [A549/ATCC]Concentration at which 50% inhibition occurs.6FloatμM
29LC50 [A549/ATCC]Concentration of a substance in units of molarity required for total growth inhibition.6FloatμM
30TGI [A549/ATCC]Concentration of a substance in units of molarity required for 50% lethal dose.6FloatμM
31Outcome [EKVX]bioassay outcome7Outcome
32GI50 [EKVX]*Concentration of a substance in units of molarity required for 50% growth inhibition.7FloatμM
33IC50 [EKVX]Concentration at which 50% inhibition occurs.7FloatμM
34LC50 [EKVX]Concentration of a substance in units of molarity required for total growth inhibition.7FloatμM
35TGI [EKVX]Concentration of a substance in units of molarity required for 50% lethal dose.7FloatμM
36Outcome [HOP-62]bioassay outcome8Outcome
37GI50 [HOP-62]*Concentration of a substance in units of molarity required for 50% growth inhibition.8FloatμM
38IC50 [HOP-62]Concentration at which 50% inhibition occurs8FloatμM
39LC50 [HOP-62]Concentration of a substance in units of molarity required for total growth inhibition.8FloatμM
40TGI [HOP-62]Concentration of a substance in units of molarity required for 50% lethal dose.8FloatμM
41Outcome [HOP-92]bioassay outcome9Outcome
42GI50 [HOP-92]*Concentration of a substance in units of molarity required for 50% growth inhibition.9FloatμM
43IC50 [HOP-92]Concentration at which 50% inhibition occurs9FloatμM
44LC50 [HOP-92]Concentration of a substance in units of molarity required for total growth inhibition.9FloatμM
45TGI [HOP-92]Concentration of a substance in units of molarity required for 50% lethal dose.9FloatμM
46Outcome [NCI-H226]bioassay outcome10Outcome
47GI50 [NCI-H226]*Concentration of a substance in units of molarity required for 50% growth inhibition.10FloatμM
48IC50 [NCI-H226]Concentration at which 50% inhibition occurs.10FloatμM
49LC50 [NCI-H226]Concentration of a substance in units of molarity required for total growth inhibition.10FloatμM
50TGI [NCI-H226]Concentration of a substance in units of molarity required for 50% lethal dose.10FloatμM
51Outcome [NCI-H322M]bioassay outcome11Outcome
52GI50 [NCI-H322M]*Concentration of a substance in units of molarity required for 50% growth inhibition.11FloatμM
53IC50 [NCI-H322M]Concentration at which 50% inhibition occurs.11FloatμM
54LC50 [NCI-H322M]Concentration of a substance in units of molarity required for total growth inhibition.11FloatμM
55TGI [NCI-H322M]Concentration of a substance in units of molarity required for 50% lethal dose.11FloatμM
56Outcome [NCI-H460]bioassay outcome12Outcome
57GI50 [NCI-H460]*Concentration of a substance in units of molarity required for 50% growth inhibition.12FloatμM
58IC50 [NCI-H460]Concentration at which 50% inhibition occurs.12FloatμM
59LC50 [NCI-H460]Concentration of a substance in units of molarity required for total growth inhibition.12FloatμM
60TGI [NCI-H460]Concentration of a substance in units of molarity required for 50% lethal dose.12FloatμM
61Outcome [NCI-H522]bioassay outcome13Outcome
62GI50 [NCI-H522]*Concentration of a substance in units of molarity required for 50% growth inhibition.13FloatμM
63IC50 [NCI-H522]Concentration at which 50% inhibition occurs.13FloatμM
64LC50 [NCI-H522]Concentration of a substance in units of molarity required for total growth inhibition.13FloatμM
65TGI [NCI-H522]Concentration of a substance in units of molarity required for 50% lethal dose.13FloatμM
66Outcome [COLO 205]bioassay outcome14Outcome
67GI50 [COLO 205]*Concentration of a substance in units of molarity required for 50% growth inhibition.14FloatμM
68IC50 [COLO 205]Concentration at which 50% inhibition occurs.14FloatμM
69LC50 [COLO 205]Concentration of a substance in units of molarity required for total growth inhibition.14FloatμM
70TGI [COLO 205]Concentration of a substance in units of molarity required for 50% lethal dose.14FloatμM
71Outcome [HCC-2998]bioassay outcome15Outcome
72GI50 [HCC-2998]*Concentration of a substance in units of molarity required for 50% growth inhibition.15FloatμM
73IC50 [HCC-2998]Concentration at which 50% inhibition occurs.15FloatμM
74LC50 [HCC-2998]Concentration of a substance in units of molarity required for total growth inhibition.15FloatμM
75TGI [HCC-2998]Concentration of a substance in units of molarity required for 50% lethal dose.15FloatμM
76Outcome [HCT-116]bioassay outcome16Outcome
77GI50 [HCT-116]*Concentration of a substance in units of molarity required for 50% growth inhibition.16FloatμM
78IC50 [HCT-116]Concentration at which 50% inhibition occurs.16FloatμM
79LC50 [HCT-116]Concentration of a substance in units of molarity required for total growth inhibition.16FloatμM
80TGI [HCT-116]Concentration of a substance in units of molarity required for 50% lethal dose.16FloatμM
81Outcome [HCT-15]bioassay outcome17Outcome
82GI50 [HCT-15]*Concentration of a substance in units of molarity required for 50% growth inhibition.17FloatμM
83IC50 [HCT-15]Concentration at which 50% inhibition occurs.17FloatμM
84LC50 [HCT-15]Concentration of a substance in units of molarity required for total growth inhibition.17FloatμM
85TGI [HCT-15]Concentration of a substance in units of molarity required for 50% lethal dose.17FloatμM
86Outcome [HT29]bioassay outcome18Outcome
87GI50 [HT29]*Concentration of a substance in units of molarity required for 50% growth inhibition.18FloatμM
88IC50 [HT29]Concentration at which 50% inhibition occurs.18FloatμM
89LC50 [HT29]Concentration of a substance in units of molarity required for total growth inhibition.18FloatμM
90TGI [HT29]Concentration of a substance in units of molarity required for 50% lethal dose.18FloatμM
91Outcome [KM12]bioassay outcome19Outcome
92GI50 [KM12]*Concentration of a substance in units of molarity required for 50% growth inhibition.19FloatμM
93IC50 [KM12]Concentration at which 50% inhibition occurs.19FloatμM
94LC50 [KM12]Concentration of a substance in units of molarity required for total growth inhibition.19FloatμM
95TGI [KM12]Concentration of a substance in units of molarity required for 50% lethal dose.19FloatμM
96Outcome [SW-620]bioassay outcome20Outcome
97GI50 [SW-620]*Concentration of a substance in units of molarity required for 50% growth inhibition.20FloatμM
98IC50 [SW-620]Concentration at which 50% inhibition occurs.20FloatμM
99LC50 [SW-620]Concentration of a substance in units of molarity required for total growth inhibition.20FloatμM
100TGI [SW-620]Concentration of a substance in units of molarity required for 50% lethal dose.20FloatμM
101Outcome [SF-268]bioassay outcome21Outcome
102GI50 [SF-268]*Concentration of a substance in units of molarity required for 50% growth inhibition.21FloatμM
103IC50 [SF-268]Concentration at which 50% inhibition occurs.21FloatμM
104LC50 [SF-268]Concentration of a substance in units of molarity required for total growth inhibition.21FloatμM
105TGI [SF-268]Concentration of a substance in units of molarity required for 50% lethal dose.21FloatμM
106Outcome [SF-295]bioassay outcome22Outcome
107GI50 [SF-295]*Concentration of a substance in units of molarity required for 50% growth inhibition.22FloatμM
108IC50 [SF-295]Concentration at which 50% inhibition occurs.22FloatμM
109LC50 [SF-295]Concentration of a substance in units of molarity required for total growth inhibition.22FloatμM
110TGI [SF-295]Concentration of a substance in units of molarity required for 50% lethal dose.22FloatμM
111Outcome [SF-539]bioassay outcome23Outcome
112GI50 [SF-539]*Concentration of a substance in units of molarity required for 50% growth inhibition.23FloatμM
113IC50 [SF-539]Concentration at which 50% inhibition occurs.23FloatμM
114LC50 [SF-539]Concentration of a substance in units of molarity required for total growth inhibition.23FloatμM
115TGI [SF-539]Concentration of a substance in units of molarity required for 50% lethal dose.23FloatμM
116Outcome [SNB-19]bioassay outcome24Outcome
117GI50 [SNB-19]*Concentration of a substance in units of molarity required for 50% growth inhibition.24FloatμM
118IC50 [SNB-19]Concentration at which 50% inhibition occurs.24FloatμM
119LC50 [SNB-19]Concentration of a substance in units of molarity required for total growth inhibition.24FloatμM
120TGI [SNB-19]Concentration of a substance in units of molarity required for 50% lethal dose.24FloatμM
121Outcome [SNB-75]bioassay outcome25Outcome
122GI50 [SNB-75]*Concentration of a substance in units of molarity required for 50% growth inhibition.25FloatμM
123IC50 [SNB-75]Concentration at which 50% inhibition occurs.25FloatμM
124LC50 [SNB-75]Concentration of a substance in units of molarity required for total growth inhibition.25FloatμM
125TGI [SNB-75]Concentration of a substance in units of molarity required for 50% lethal dose.25FloatμM
126Outcome [U251]bioassay outcome26Outcome
127GI50 [U251]*Concentration of a substance in units of molarity required for 50% growth inhibition.26FloatμM
128IC50 [U251]Concentration at which 50% inhibition occurs.26FloatμM
129LC50 [U251]Concentration of a substance in units of molarity required for total growth inhibition.26FloatμM
130TGI [U251]Concentration of a substance in units of molarity required for 50% lethal dose.26FloatμM
131Outcome [LOX IMVI]bioassay outcome27Outcome
132GI50 [LOX IMVI]*Concentration of a substance in units of molarity required for 50% growth inhibition.27FloatμM
133IC50 [LOX IMVI]Concentration at which 50% inhibition occurs.27FloatμM
134LC50 [LOX IMVI]Concentration of a substance in units of molarity required for total growth inhibition.27FloatμM
135TGI [LOX IMVI]Concentration of a substance in units of molarity required for 50% lethal dose.27FloatμM
136Outcome [MALME-3M]bioassay outcome28Outcome
137GI50 [MALME-3M]*Concentration of a substance in units of molarity required for 50% growth inhibition.28FloatμM
138IC50 [MALME-3M]Concentration at which 50% inhibition occurs.28FloatμM
139LC50 [MALME-3M]Concentration of a substance in units of molarity required for total growth inhibition.28FloatμM
140TGI [MALME-3M]Concentration of a substance in units of molarity required for 50% lethal dose.28FloatμM
141Outcome [M14]bioassay outcome29Outcome
142GI50 [M14]*Concentration of a substance in units of molarity required for 50% growth inhibition.29FloatμM
143IC50 [M14]Concentration at which 50% inhibition occurs.29FloatμM
144LC50 [M14]Concentration of a substance in units of molarity required for total growth inhibition.29FloatμM
145TGI [M14]Concentration of a substance in units of molarity required for 50% lethal dose.29FloatμM
146Outcome [MDA-MB-435]bioassay outcome30Outcome
147GI50 [MDA-MB-435]*Concentration of a substance in units of molarity required for 50% growth inhibition.30FloatμM
148IC50 [MDA-MB-435]Concentration at which 50% inhibition occurs.30FloatμM
149LC50 [MDA-MB-435]Concentration of a substance in units of molarity required for total growth inhibition.30FloatμM
150TGI [MDA-MB-435]Concentration of a substance in units of molarity required for 50% lethal dose.30FloatμM
151Outcome [SK-MEL-2]bioassay outcome31Outcome
152GI50 [SK-MEL-2]*Concentration of a substance in units of molarity required for 50% growth inhibition.31FloatμM
153IC50 [SK-MEL-2]Concentration at which 50% inhibition occurs.31FloatμM
154LC50 [SK-MEL-2]Concentration of a substance in units of molarity required for total growth inhibition.31FloatμM
155TGI [SK-MEL-2]Concentration of a substance in units of molarity required for 50% lethal dose.31FloatμM
156Outcome [SK-MEL-28]bioassay outcome32Outcome
157GI50 [SK-MEL-28]*Concentration of a substance in units of molarity required for 50% growth inhibition.32FloatμM
158IC50 [SK-MEL-28]Concentration at which 50% inhibition occurs.32FloatμM
159LC50 [SK-MEL-28]Concentration of a substance in units of molarity required for total growth inhibition.32FloatμM
160TGI [SK-MEL-28]Concentration of a substance in units of molarity required for 50% lethal dose.32FloatμM
161Outcome [UACC-257]bioassay outcome33Outcome
162GI50 [UACC-257]*Concentration of a substance in units of molarity required for 50% growth inhibition.33FloatμM
163IC50 [UACC-257]Concentration at which 50% inhibition occurs.33FloatμM
164LC50 [UACC-257]Concentration of a substance in units of molarity required for total growth inhibition.33FloatμM
165TGI [UACC-257]Concentration of a substance in units of molarity required for 50% lethal dose.33FloatμM
166Outcome [UACC-62]bioassay outcome34Outcome
167GI50 [UACC-62]*Concentration of a substance in units of molarity required for 50% growth inhibition.34FloatμM
168IC50 [UACC-62]Concentration at which 50% inhibition occurs.34FloatμM
169LC50 [UACC-62]Concentration of a substance in units of molarity required for total growth inhibition.34FloatμM
170TGI [UACC-62]Concentration of a substance in units of molarity required for 50% lethal dose.34FloatμM
171Outcome [IGROV1]bioassay outcome35Outcome
172GI50 [IGROV1]*Concentration of a substance in units of molarity required for 50% growth inhibition.35FloatμM
173IC50 [IGROV1]Concentration at which 50% inhibition occurs.35FloatμM
174LC50 [IGROV1]Concentration of a substance in units of molarity required for total growth inhibition.35FloatμM
175TGI [IGROV1]Concentration of a substance in units of molarity required for 50% lethal dose.35FloatμM
176Outcome [OVCAR-3]bioassay outcome36Outcome
177GI50 [OVCAR-3]*Concentration of a substance in units of molarity required for 50% growth inhibition.36FloatμM
178IC50 [OVCAR-3]Concentration at which 50% inhibition occurs.36FloatμM
179LC50 [OVCAR-3]concentration of a substance in units of molarity required for total growth inhibition.36FloatμM
180TGI [OVCAR-3]Concentration of a substance in units of molarity required for 50% lethal dose.36FloatμM
181Outcome [OVCAR-4]bioassay outcome37Outcome
182GI50 [OVCAR-4]*Concentration of a substance in units of molarity required for 50% growth inhibition.37FloatμM
183IC50 [OVCAR-4]Concentration at which 50% inhibition occurs.37FloatμM
184LC50 [OVCAR-4]Concentration of a substance in units of molarity required for total growth inhibition.37FloatμM
185TGI [OVCAR-4]Concentration of a substance in units of molarity required for 50% lethal dose.37FloatμM
186Outcome [OVCAR-5]bioassay outcome38Outcome
187GI50 [OVCAR-5]*Concentration of a substance in units of molarity required for 50% growth inhibition.38FloatμM
188IC50 [OVCAR-5]Concentration at which 50% inhibition occurs.38FloatμM
189LC50 [OVCAR-5]Concentration of a substance in units of molarity required for total growth inhibition.38FloatμM
190TGI [OVCAR-5]Concentration of a substance in units of molarity required for 50% lethal dose.38FloatμM
191Outcome [OVCAR-8]bioassay outcome39Outcome
192GI50 [OVCAR-8]*Concentration of a substance in units of molarity required for 50% growth inhibition.39FloatμM
193IC50 [OVCAR-8]Concentration at which 50% inhibition occurs.39FloatμM
194LC50 [OVCAR-8]Concentration of a substance in units of molarity required for total growth inhibition.39FloatμM
195TGI [OVCAR-8]Concentration of a substance in units of molarity required for 50% lethal dose.39FloatμM
196Outcome [NCI/ADR-RES]bioassay outcome40Outcome
197GI50 [NCI/ADR-RES]*Concentration of a substance in units of molarity required for 50% growth inhibition.40FloatμM
198IC50 [NCI/ADR-RES]Concentration at which 50% inhibition occurs.40FloatμM
199LC50 [NCI/ADR-RES]Concentration of a substance in units of molarity required for total growth inhibition.40FloatμM
200TGI [NCI/ADR-RES]Concentration of a substance in units of molarity required for 50% lethal dose.40FloatμM
201Outcome [SK-OV-3]bioassay outcome41Outcome
202GI50 [SK-OV-3]*Concentration of a substance in units of molarity required for 50% growth inhibition.41FloatμM
203IC50 [SK-OV-3]Concentration at which 50% inhibition occurs41FloatμM
204LC50 [SK-OV-3]Concentration of a substance in units of molarity required for total growth inhibition.41FloatμM
205TGI [SK-OV-3]Concentration of a substance in units of molarity required for 50% lethal dose.41FloatμM
206Outcome [786-0]bioassay outcome42Outcome
207GI50 [786-0]*Concentration of a substance in units of molarity required for 50% growth inhibition.42FloatμM
208IC50 [786-0]Concentration at which 50% inhibition occurs.42FloatμM
209LC50 [786-0]Concentration of a substance in units of molarity required for total growth inhibition.42FloatμM
210TGI [786-0]Concentration of a substance in units of molarity required for 50% lethal dose.42FloatμM
211Outcome [A498]bioassay outcome43Outcome
212GI50 [A498]*Concentration of a substance in units of molarity required for 50% growth inhibition.43FloatμM
213IC50 [A498]Concentration at which 50% inhibition occurs.43FloatμM
214LC50 [A498]Concentration of a substance in units of molarity required for total growth inhibition.43FloatμM
215TGI [A498]Concentration of a substance in units of molarity required for 50% lethal dose.43FloatμM
216Outcome [ACHN]bioassay outcome44Outcome
217GI50 [ACHN]*Concentration of a substance in units of molarity required for 50% growth inhibition.44FloatμM
218IC50 [ACHN]Concentration at which 50% inhibition occurs.44FloatμM
219LC50 [ACHN]Concentration of a substance in units of molarity required for total growth inhibition.44FloatμM
220TGI [ACHN]Concentration of a substance in units of molarity required for 50% lethal dose.44FloatμM
221Outcome [CAKI-1]bioassay outcome45Outcome
222GI50 [CAKI-1]*Concentration of a substance in units of molarity required for 50% growth inhibition.45FloatμM
223IC50 [CAKI-1]Concentration at which 50% inhibition occurs.45FloatμM
224LC50 [CAKI-1]Concentration of a substance in units of molarity required for total growth inhibition.45FloatμM
225TGI [CAKI-1]Concentration of a substance in units of molarity required for 50% lethal dose.45FloatμM
226Outcome [RXF 393]bioassay outcome46Outcome
227GI50 [RXF 393]*Concentration of a substance in units of molarity required for 50% growth inhibition.46FloatμM
228IC50 [RXF 393]Concentration at which 50% inhibition occurs.46FloatμM
229LC50 [RXF 393]Concentration of a substance in units of molarity required for total growth inhibition.46FloatμM
230TGI [RXF 393]Concentration of a substance in units of molarity required for 50% lethal dose.46FloatμM
231Outcome [SN12C]bioassay outcome47Outcome
232GI50 [SN12C]*Concentration of a substance in units of molarity required for 50% growth inhibition.47FloatμM
233IC50 [SN12C]Concentration at which 50% inhibition occurs.47FloatμM
234LC50 [SN12C]Concentration of a substance in units of molarity required for total growth inhibition.47FloatμM
235TGI [SN12C]Concentration of a substance in units of molarity required for 50% lethal dose.47FloatμM
236Outcome [TK-10]bioassay outcome48Outcome
237GI50 [TK-10]*Concentration of a substance in units of molarity required for 50% growth inhibition.48FloatμM
238IC50 [TK-10]Concentration at which 50% inhibition occurs.48FloatμM
239LC50 [TK-10]Concentration of a substance in units of molarity required for total growth inhibition.48FloatμM
240TGI [TK-10]Concentration of a substance in units of molarity required for 50% lethal dose.48FloatμM
241Outcome [UO-31]bioassay outcome49Outcome
242GI50 [UO-31]*Concentration of a substance in units of molarity required for 50% growth inhibition.49FloatμM
243IC50 [UO-31]Concentration at which 50% inhibition occurs.49FloatμM
244LC50 [UO-31]Concentration of a substance in units of molarity required for total growth inhibition.49FloatμM
245TGI [UO-31]Concentration of a substance in units of molarity required for 50% lethal dose.49FloatμM
246Outcome [PC-3]bioassay outcome50Outcome
247GI50 [PC-3]*Concentration of a substance in units of molarity required for 50% growth inhibition.50FloatμM
248IC50 [PC-3]Concentration at which 50% inhibition occurs.50FloatμM
249LC50 [PC-3]Concentration of a substance in units of molarity required for total growth inhibition.50FloatμM
250TGI [PC-3]Concentration of a substance in units of molarity required for 50% lethal dose.50FloatμM
251Outcome [DU-145]bioassay outcome51Outcome
252GI50 [DU-145]*Concentration of a substance in units of molarity required for 50% growth inhibition.51FloatμM
253IC50 [DU-145]Concentration at which 50% inhibition occurs51FloatμM
254LC50 [DU-145]Concentration of a substance in units of molarity required for total growth inhibition.51FloatμM
255TGI [DU-145]Concentration of a substance in units of molarity required for 50% lethal dose.51FloatμM
256Outcome [MCF7]bioassay outcome52Outcome
257GI50 [MCF7]*Concentration of a substance in units of molarity required for 50% growth inhibition.52FloatμM
258IC50 [MCF7]Concentration at which 50% inhibition occurs.52FloatμM
259LC50 [MCF7]Concentration of a substance in units of molarity required for total growth inhibition.52FloatμM
260TGI [MCF7]Concentration of a substance in units of molarity required for 50% lethal dose.52FloatμM
261Outcome [MDA-MB-231/ATCC]bioassay outcome53Outcome
262GI50 [MDA-MB-231/ATCC]*Concentration of a substance in units of molarity required for 50% growth inhibition.53FloatμM
263IC50 [MDA-MB-231/ATCC]Concentration at which 50% inhibition occurs.53FloatμM
264LC50 [MDA-MB-231/ATCC]Concentration of a substance in units of molarity required for total growth inhibition.53FloatμM
265TGI [MDA-MB-231/ATCC]Concentration of a substance in units of molarity required for 50% lethal dose.53FloatμM
266Outcome [HS 578T]bioassay outcome54Outcome
267GI50 [HS 578T]*Concentration of a substance in units of molarity required for 50% growth inhibition.54FloatμM
268IC50 [HS 578T]Concentration at which 50% inhibition occurs.54FloatμM
269LC50 [HS 578T]Concentration of a substance in units of molarity required for total growth inhibition.54FloatμM
270TGI [HS 578T]Concentration of a substance in units of molarity required for 50% lethal dose.54FloatμM
271Outcome [BT-549]bioassay outcome55Outcome
272GI50 [BT-549]*Concentration of a substance in units of molarity required for 50% growth inhibition.55FloatμM
273IC50 [BT-549]Concentration at which 50% inhibition occurs.55FloatμM
274LC50 [BT-549]Concentration of a substance in units of molarity required for total growth inhibition.55FloatμM
275TGI [BT-549]Concentration of a substance in units of molarity required for 50% lethal dose.55FloatμM
276Outcome [T-47D]bioassay outcome56Outcome
277GI50 [T-47D]*Concentration of a substance in units of molarity required for 50% growth inhibition.56FloatμM
278IC50 [T-47D]Concentration at which 50% inhibition occurs.56FloatμM
279LC50 [T-47D]Concentration of a substance in units of molarity required for total growth inhibition.56FloatμM
280TGI [T-47D]Concentration of a substance in units of molarity required for 50% lethal dose.56FloatμM

* Activity Concentration. § Panel component ID.
Additional Information
Grant Number: 1-R03-DA026215-01

PageFrom: